Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen

Principal Investigator: Chatta, Gurkamal S

A032102: PRECISION DIAGNOSTICS IN PROSTATE CANCER TREATMENT (PREDICT)

Principal Investigator: Chatta, Gurkamal S

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Principal Investigator: Chatta, Gurkamal S

Investigating The Effect of Testosterone Replacement Therapy Among Hypogonadal Men with Localized Prostate Cancer on Active Surveillance

Principal Investigator: Aly, Ahmed A

Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Principal Investigator: Chatta, Gurkamal S

PHASE 1/2 STUDY OF REGN4336 (A PSMAXCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB OR REGN5678 (A PSMAxCD28 BISPECIFIC ANTIBODY) IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Principal Investigator: Chatta, Gurkamal S

NRG-GU011: A PHASE II DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC
RADIOTHERAPY WITH OR WITHOUT ANDROGEN
DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE
CANCER (NRG PROMETHEAN)

Principal Investigator: Kuettel, Michael R

Investigating the Correlation Between the Brain and Pelvic Floor Muscle Activity of
Patients who had or are Undergoing Robot-Assisted Radical Prostatectomy

Principal Investigator: Guru, Khurshid

Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-induced Obese Frailty in Survivors of Advanced Prostate Cancer

Principal Investigator: Chatta, Gurkamal S